Research & Development

Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

Sanofi’s vaccines global business unit Sanofi Pasteur has collaborated with Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease

Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines

The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible.

Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19

Xencor and Vir Biotechnology have entered into a technology licence agreement for the use of Xtend XmAb Fc technology in investigational antibodies for the treatment of COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders

Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions.

Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections

Healthcare biotechnology company Entos Pharmaceuticals has unveiled plans to develop a Fusogenix DNA vaccine for the prevention of COVID-19 infections.

RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").

Pfizer, BioNTech collaborate to develop vaccine for COVID-19

Pfizer has collaborated with Biopharmaceutical New Technologies (BioNTech) for the co-development of a potential COVID-19 vaccine.

AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or approximately $14.4 million as of the close of trading on March 13, 2020, plus a contingent value right (CVR).